These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 32606205)

  • 21. (2R,6R)-hydroxynorketamine rapidly potentiates optically-evoked Schaffer collateral synaptic activity.
    Riggs LM; Thompson SM; Gould TD
    Neuropharmacology; 2022 Aug; 214():109153. PubMed ID: 35661657
    [TBL] [Abstract][Full Text] [Related]  

  • 22. BDNF-TrkB signaling-mediated upregulation of Narp is involved in the antidepressant-like effects of (2R,6R)-hydroxynorketamine in a chronic restraint stress mouse model.
    Ju L; Yang J; Zhu T; Liu P; Yang J
    BMC Psychiatry; 2022 Mar; 22(1):182. PubMed ID: 35291971
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Brain-derived neurotrophic factor in the ventrolateral periaqueductal gray contributes to (2R,6R)-hydroxynorketamine-mediated actions.
    Chou D
    Neuropharmacology; 2020 Jun; 170():108068. PubMed ID: 32222405
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Target deconvolution studies of (2R,6R)-hydroxynorketamine: an elusive search.
    Bonaventura J; Gomez JL; Carlton ML; Lam S; Sanchez-Soto M; Morris PJ; Moaddel R; Kang HJ; Zanos P; Gould TD; Thomas CJ; Sibley DR; Zarate CA; Michaelides M
    Mol Psychiatry; 2022 Oct; 27(10):4144-4156. PubMed ID: 35768639
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Mouse, rat, and dog bioavailability and mouse oral antidepressant efficacy of (
    Highland JN; Morris PJ; Zanos P; Lovett J; Ghosh S; Wang AQ; Zarate CA; Thomas CJ; Moaddel R; Gould TD
    J Psychopharmacol; 2019 Jan; 33(1):12-24. PubMed ID: 30488740
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Molecular mechanisms of the rapid-acting and long-lasting antidepressant actions of (R)-ketamine.
    Hashimoto K
    Biochem Pharmacol; 2020 Jul; 177():113935. PubMed ID: 32224141
    [TBL] [Abstract][Full Text] [Related]  

  • 27. NMDAR inhibition-independent antidepressant actions of ketamine metabolites.
    Zanos P; Moaddel R; Morris PJ; Georgiou P; Fischell J; Elmer GI; Alkondon M; Yuan P; Pribut HJ; Singh NS; Dossou KS; Fang Y; Huang XP; Mayo CL; Wainer IW; Albuquerque EX; Thompson SM; Thomas CJ; Zarate CA; Gould TD
    Nature; 2016 May; 533(7604):481-6. PubMed ID: 27144355
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Sex-dependent metabolism of ketamine and (
    Highland JN; Farmer CA; Zanos P; Lovett J; Zarate CA; Moaddel R; Gould TD
    J Psychopharmacol; 2022 Feb; 36(2):170-182. PubMed ID: 34971525
    [TBL] [Abstract][Full Text] [Related]  

  • 29. NMDA Receptor Activation-Dependent Antidepressant-Relevant Behavioral and Synaptic Actions of Ketamine.
    Zanos P; Brown KA; Georgiou P; Yuan P; Zarate CA; Thompson SM; Gould TD
    J Neurosci; 2023 Feb; 43(6):1038-1050. PubMed ID: 36596696
    [TBL] [Abstract][Full Text] [Related]  

  • 30. (2
    Kang H; Park P; Han M; Tidball P; Georgiou J; Bortolotto ZA; Lodge D; Kaang BK; Collingridge GL
    Brain Neurosci Adv; 2020; 4():2398212820957847. PubMed ID: 33088919
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Ketamine increases vmPFC activity: Effects of (R)- and (S)-stereoisomers and (2R,6R)-hydroxynorketamine metabolite.
    Hare BD; Pothula S; DiLeone RJ; Duman RS
    Neuropharmacology; 2020 Apr; 166():107947. PubMed ID: 31926944
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Mechanisms of ketamine action as an antidepressant.
    Zanos P; Gould TD
    Mol Psychiatry; 2018 Apr; 23(4):801-811. PubMed ID: 29532791
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Mechanisms of ketamine and its metabolites as antidepressants.
    Hess EM; Riggs LM; Michaelides M; Gould TD
    Biochem Pharmacol; 2022 Mar; 197():114892. PubMed ID: 34968492
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A comparison of the pharmacokinetics and NMDAR antagonism-associated neurotoxicity of ketamine, (2R,6R)-hydroxynorketamine and MK-801.
    Morris PJ; Burke RD; Sharma AK; Lynch DC; Lemke-Boutcher LE; Mathew S; Elayan I; Rao DB; Gould TD; Zarate CA; Zanos P; Moaddel R; Thomas CJ
    Neurotoxicol Teratol; 2021; 87():106993. PubMed ID: 33945878
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Mediation of the behavioral effects of ketamine and (2R,6R)-hydroxynorketamine in mice by kappa opioid receptors.
    Wulf HA; Browne CA; Zarate CA; Lucki I
    Psychopharmacology (Berl); 2022 Jul; 239(7):2309-2316. PubMed ID: 35459958
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Lack of Antidepressant Effects of (2R,6R)-Hydroxynorketamine in a Rat Learned Helplessness Model: Comparison with (R)-Ketamine.
    Shirayama Y; Hashimoto K
    Int J Neuropsychopharmacol; 2018 Jan; 21(1):84-88. PubMed ID: 29155993
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Hydroxynorketamine: Implications for the NMDA Receptor Hypothesis of Ketamine's Antidepressant Action.
    Aleksandrova LR; Wang YT; Phillips AG
    Chronic Stress (Thousand Oaks); 2017; 1():. PubMed ID: 30556028
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Ketamine metabolite (2R,6R)-hydroxynorketamine reverses behavioral despair produced by adolescent trauma.
    Elmer GI; Tapocik JD; Mayo CL; Zanos P; Gould TD
    Pharmacol Biochem Behav; 2020 Sep; 196():172973. PubMed ID: 32569786
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Proteomic Study Reveals the Involvement of Energy Metabolism in the Fast Antidepressant Effect of (2R, 6R)-Hydroxy Norketamine.
    Rahman SU; Hao Q; He K; Li Y; Yang X; Ye T; Ali T; Zhou Q; Li S
    Proteomics Clin Appl; 2020 Jul; 14(4):e1900094. PubMed ID: 32080978
    [TBL] [Abstract][Full Text] [Related]  

  • 40. cAMP-dependent protein kinase signaling is required for (
    Riggs LM; Pereira EFR; Thompson SM; Gould TD
    J Neurophysiol; 2024 Jan; 131(1):64-74. PubMed ID: 38050689
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.